Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: modernatx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $40.00 | Neutral | Citigroup |
| 2/18/2025 | $111.00 → $45.00 | Overweight → Equal Weight | Barclays |
| 1/29/2025 | $99.00 → $51.00 | Buy → Neutral | Goldman |
| 12/18/2024 | Buy → Hold | Argus | |
| 12/10/2024 | $41.00 | Underperform | BofA Securities |
| 11/19/2024 | $42.00 | Hold | Berenberg |
| 11/18/2024 | $58.00 | Hold → Buy | HSBC Securities |
| 11/15/2024 | $40.00 | Underperform | Wolfe Research |
| 10/17/2024 | $55.00 | Mkt Perform | Bernstein |
| 9/13/2024 | $120.00 → $65.00 | Buy → Hold | Jefferies |
10-Q - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
SCHEDULE 13G - Moderna, Inc. (0001682852) (Subject)
8-K - Moderna, Inc. (0001682852) (Filer)
10-Q - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
SCHEDULE 13G/A - Moderna, Inc. (0001682852) (Subject)
DEFA14A - Moderna, Inc. (0001682852) (Filer)
DEF 14A - Moderna, Inc. (0001682852) (Filer)
S-8 - Moderna, Inc. (0001682852) (Filer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
Live FDA approvals issued by the Food and Drug Administration and FDA breaking news
For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Citigroup initiated coverage of Moderna with a rating of Neutral and set a new price target of $40.00
Barclays downgraded Moderna from Overweight to Equal Weight and set a new price target of $45.00 from $111.00 previously
Goldman downgraded Moderna from Buy to Neutral and set a new price target of $51.00 from $99.00 previously
Argus downgraded Moderna from Buy to Hold
BofA Securities resumed coverage of Moderna with a rating of Underperform and set a new price target of $41.00
Berenberg initiated coverage of Moderna with a rating of Hold and set a new price target of $42.00
HSBC Securities upgraded Moderna from Hold to Buy and set a new price target of $58.00
Wolfe Research initiated coverage of Moderna with a rating of Underperform and set a new price target of $40.00
Bernstein initiated coverage of Moderna with a rating of Mkt Perform and set a new price target of $55.00
Jefferies downgraded Moderna from Buy to Hold and set a new price target of $65.00 from $120.00 previously
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
Fastest customizable press release news feed in the world
Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger. Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co
Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod
Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating
CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec
Etiome's Temporal Biodynamics™ AI-powered platform is the first end-to-end solution to detect disease and preempt progression before it becomes too late Company emerges following four years of platform development and an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., April 24, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Etiome, a company redefining how we detect and preempt disease progression. Etiome's Temporal Biodynamics™ platform is the first end-to-end technology to characterize disease with increased resolution over time and accelerate the development of preemptive medicines that promise better health outcom
Believes Company's Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track's View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax's Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDA
Collaboration leverages Logica, a platform offering from Valo Health and Charles River that directly translates biological insights into optimized small molecules Sixth agreement signed under strategic partnership between Flagship Pioneering and Pfizer to accelerate discovery of innovative compounds that may become medicines targeting unmet needs CAMBRIDGE, Mass., April 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement between Pioneering Medicines, Flagship's in-house drug discovery and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.
First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering's in-house drug development unit Charles River Laboratories International, Inc. (NYSE:CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need. The discovery is the first using Logica®, an artificial intelligence (AI)-powered drug development solution that translates biological insights into optimized preclinical assets. "Identification of this first lead candidate provides proof-of-concept for Logica as a
AI platform combined with autonomous labs will accelerate discovery across every domain of science Company has raised $200M in seed financing to further develop platform and build first AI Science Factories CAMBRIDGE, Mass., March 10, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Lila Sciences, a company building the world's first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences. The company, which was founded in Flagship's labs in 2023, is pioneering an advanced form of AI that can not only process vast amounts of data and make predictions, but also assist scientists in designing and con
Issues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well
Live Leadership Updates
Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger. Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co
Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating
CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec
Owen joins to lead new phase of growth for the medical device company in clinical trial, diagnostic, and reference laboratory applications CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and YourBio Health, a pioneer in remote blood collection technology, today announced the appointment of Paul Owen as Chief Executive Officer of YourBio Health and CEO-Partner of Flagship Pioneering. Owen joins YourBio Health and Flagship after a corporate leadership and strategic planning career spanning more than 35 years. He was most r
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
Valo Elevates Brett Blackman to Chief Operating Officer and Appoints Travis Wilson to its Board of Directors CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been appointed Chief Executive Officer of Valo Health and CEO-Partner of Flagship Pioneering. Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center (BRIC), for Roche/Genentech and previously as CEO of Foundation Medicine. Valo also announced the appointments of Brett Blackman
CAMBRIDGE, Masss. and LONDON, Oct. 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Junaid Bajwa, M.D., has joined its London office as Senior Partner and Head of United Kingdom. In this role, Dr. Bajwa will play an integral role in advancing new strategic opportunities and partnerships for Flagship and its ecosystem of companies in the United Kingdom and throughout Europe. Dr. Bajwa will also serve as Science Partner for Pioneering Intelligence, Flagship's strategic initiative that is building unique AI/ML knowledge to accelerate innovation across the ecosystem.
CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Paul Parker has joined as Managing Partner, Capital Solutions and Value Realization. In this role, Parker will lead all capital solutions efforts at Flagship, driving portfolio value realization, fundraising activities, and building and managing Flagship's relationships with Limited Partners as well as strategic and financial investors. He will also play a key role on Flagship's senior leadership team, helping drive value, impact, and effectiveness across the organization.
CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio. Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, where he and Ignacio Martinez are responsible partners for Invaio. He is also Senior Partner
Live finance-specific insights
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the adv
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billionReceived U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in JuneAnnounced positive Phase 3 data for combination vaccine against influenza and COVID-19Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024."During the second quarter, we marked the approval of our
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advance
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billionInitiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinomaAdvanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor eventCAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Mod
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancemen
Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valuation allowanceReaffirms 2024 expected product sales of approximately $4 billionExpects regulatory approvals for its investigational RSV vaccine for older adults beginning in first half of 2024, and anticipates additional key milestones from its late-stage pipeline this yearCAMBRIDGE, MA / ACCESSWIRE / February 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial result
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine.
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to date increased to 45% from 36% in 2022Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowanceCompany's late-stage pipeline has six Phase 3 programsCompany expects to break even in 2026 through product launches and disciplined investmentCAMBRIDGE, MA / ACCESSWIRE / November 2,
CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaIn over 10 years since its inception, Moderna has transformed from a research-stage
This live feed shows all institutional transactions in real time.
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)